Evidence map›Paper›PMID 39466203›Full record

ArticleThe Journal of experimental medicine2024

Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection.

Weiwei Sun, Ce Gao, Gregory Takashi Gladkov, Isabelle Roseto, Leah Carrere, Elizabeth M Parsons, Carmen Gasca-Capote, John Frater, Sarah Fidler, Xu G Yu and 2 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. The HIV reservoir landscape in elite controllers.Current opinion in HIV and AIDS · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weiwei SunRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0002-4578-6292
Ce GaoRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0002-3775-790X
Gregory Takashi GladkovRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0003-0206-6575
Isabelle RosetoRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0009-0008-2976-0720
Leah CarrereRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0009-0000-2481-5501
Elizabeth M ParsonsRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0002-5962-3283
Carmen Gasca-CapoteRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0002-7211-8599
John FraterNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-7163-7277
Sarah FidlerDepartment of Infectious Disease, Imperial College and Imperial College NIHR Biomedical Research Centre, London, UK.ORCID 0000-0003-1676-7583
Xu G YuRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0002-8295-884X
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard , Cambridge, MA, USA.ORCID 0000-0001-9865-8350
RIVER Trial Study Group

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4M
Elite controllers as a model for a cure of HIV-1 infectionR37AI155171 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Xu Yu · 2020 to 2026
$5.2M
Single-cell Proteogenomic profiling of HIV-1 reservoir cellsR01AI176579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2023 to 2026
$4.6M
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 InfectionR01AI078799 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2008 to 2017
$4.1M
Selection and Evolution of HIV-1 reservoir cells in blood and tissuesR01AI152979 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ESTES, JACOB D, LICHTERFELD, MATHIAS · 2020 to 2025
$3.8M
Molecular profile of proviral reservoirs in HIV-infected drug usersR61DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2018 to 2020
$3.4M
A systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3M
Immune selection of HIV-1 reservoir cells in human clinical trialsR01AI184094 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2024 to 2026
$2.7M
amfAR, The Foundation for AIDS Research 110393-72-RPRLMedical Research Council MR/L006588/1NHLBI NIH HHS R01 HL134539NIAID NIH HHS K24 AI155233NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI152979NIAID NIH HHS R01 AI176579NIAID NIH HHS R01 AI184094NIAID NIH HHS R21 AI116228NIAID NIH HHS R33 AI116228NIAID NIH HHS R37 AI155171NIAID NIH HHS U01 AI135940NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034NIH HHS AI184094NIMH NIH HHS R01 MH134823
6 · The paper itself

Abstract

Antiretroviral treatment (ART) initiation during the early stages of HIV-1 infection is associated with a higher probability of maintaining drug-free viral control during subsequent treatment interruptions, for reasons that remain unclear. Using samples from a randomized-controlled human clinical trial evaluating therapeutic HIV-1 vaccines, we here show that early ART commencement is frequently associated with accelerated and efficient selection of genome-intact HIV-1 proviruses in repressive chromatin locations during the first year after treatment initiation. This selection process was unaffected by vaccine-induced HIV-1-specific T cell responses. Single-cell proteogenomic profiling demonstrated that cells harboring intact HIV-1 displayed a discrete phenotypic signature of immune selection by innate immune responses, characterized by a slight but significant upregulation of HLA-C, HLA-G, the IL-10 receptor, and other markers involved in innate immune regulation. Together, these results suggest an accelerated immune selection of viral reservoir cells during early-treated HIV-1 infection that seems at least partially driven by innate immune responses.

Indexed as

HIV-1HIV InfectionsImmunity, InnateAIDS VaccinesHumansMaleProvirusesRandomized Controlled Trials as TopicAIDS Vaccines

Identifiers

PMID39466203
PMCPMC11519379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.